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Abstract
Traumatic brain injury (TBI) is a devastating event for which current therapies are limited. Stem cell transplantation may lead to
recovery of function via different mechanisms, such as cell replacement through differentiation, stimulation of angiogenesis and
support to the microenvironment. Adult hair follicle bulge-derived stem cells (HFBSCs) possess neuronal differentiation capacity,
are easy to harvest and are relatively immune-privileged, which makes them potential candidates for autologous stem cell-based
therapy. In this study, we apply in vivo multimodal, optical and magnetic resonance imaging techniques to investigate the behavior
of mouse HFBSCs in a mouse model of TBI. HFBSCs expressed Luc2 and copGFP and were examined for their differentiation
capacity in vitro. Subsequently, transduced HFBSCs, preloaded with ferumoxytol, were transplanted next to the TBI lesion (cortical
region) in nude mice, 2 days after injury. Brains were fixed for immunohistochemistry 58 days after transplantation. Luc2- and
copGFP-expressing, ferumoxytol-loaded HFBSCs showed adequate neuronal differentiation potential in vitro. Bioluminescence of
the lesioned brain revealed survival of HFBSCs and magnetic resonance imaging identified their localization in the area of
transplantation. Immunohistochemistry showed that transplanted cells stained for nestin and neurofilament protein (NF-Pan).
Cells also expressed laminin and fibronectin but extracellular matrix masses were not detected. After 58 days, ferumoxytol could
be detected in HFBSCs in brain tissue sections. These results show that HFBSCs are able to survive after brain transplantation and
suggest that cells may undergo differentiation towards a neuronal cell lineage, which supports their potential use for cell-based
therapy for TBI.
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Introduction
In recent years, stem cell therapy has attracted huge interest as
a new therapeutic method for the treatment of brain injury.
Many studies using animal models and even human clinical
trials have demonstrated the potential of stem cell transplan-
tation for the treatment of neurological disorders (Hasan et al.
2017; Lemmens and Steinberg 2013). The goal of stem cell
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s00441-020-03173-1) contains supplementary
material, which is available to authorized users.
* Laura Mezzanotte
l.mezzanotte@erasmusmc.nl
1 Department of Otorhinolaryngology and Head & Neck Surgery,
Leiden University Medical Center, Leiden, the Netherlands
2 Percuros B.V, Leiden, the Netherlands
3 Max Planck Institute for Metabolism Research, Cologne, Germany
4 Translational Nanobiomaterials and Imaging, Department of
Radiology, Leiden University Medical Center, Leiden, the
Netherlands
5 Department of Radiology, Leiden University Medical Center,
Leiden, the Netherlands
6 Leiden Institute for Brain and Cognition, Leiden University,
Leiden, the Netherlands
7 Optical Molecular Imaging, Department of Radiology and Nuclear
Medicine, Erasmus Medical Center, Rotterdam, the Netherlands
8 Department of Molecular Genetics, Erasmus Medical Center,
Rotterdam, the Netherlands
9 Hair Science Institute, Maastricht, the Netherlands
Cell and Tissue Research
https://doi.org/10.1007/s00441-020-03173-1
therapy is the formation of new tissue to replace damaged
tissue by utilizing the regenerative capacity of stem cells
(Kiasatdolatabadi et al. 2017).
Application of autologous stem cells, such as bone marrow-
derived mesenchymal stromal cells (BM-MSCs) and human
umbilical cord blood cells, could induce neuro-restorative ef-
fects in the brain after injury (Bang et al. 2016; Caplan 2017).
In general, these effects are mainly attributed to paracrine
mechanisms such as the stimulatory effect of stem cells on
endogenous cells to release growth and trophic factors.
Mesenchymal stromal cells have the ability to migrate (Ngen
et al. 2015), differentiate in neural precursor cells in vitro
(Alexanian et al. 2008) and contribute to neuronal repair due
to their immunomodulatory properties and other mechanisms
(Li and Chopp 2009; Munoz et al. 2005; Zanier et al. 2014;
Zhao et al. 2016). The advantage of BM-MSCs is that they can
be harvested from the patient allowing autologous stem cell
therapy. Furthermore, the latter allows the conduction of clin-
ical trials using BM-MSCs in patients with traumatic brain
injury (TBI) (Cox 2006; Cox 2012; SanBio 2016). However,
their mesodermal potency poses a risk for unwanted differen-
tiation after transplantation (Grigoriadis et al. 2011).
An alternative could be the use of autologous adult neural
progenitor stem cells that can be isolated from easily accessi-
ble tissues in the adult body, such as periodontal ligament
surrounding the teeth, soft palate, inferior turbinate, or hair
follicles (Fernandes et al. 2004; Hauser et al. 2012; Sieber-
Blum and Grim 2004; Techawattanawisal et al. 2007). These
stem cells derive from a rich source of multipotent stem cells
called the neural crest. It has been shown that neural crest-
derived stem cells (NCSCs), harvested from adult hair folli-
cles and implanted in a lesioned spinal cord, resulted in the
production of cells that fulfill most criteria for a genuine neu-
ronal differentiation (Hu et al. 2010). For cell-based therapy,
the use of NCSCs from the hair follicle bulge (or hair follicle
bulge-derived stem cells, HFBSCs) has several advantages
above using other stem cell types, such as embryonic stem
cells and neural stem cells. These advantages are (i) they are
abundant and easily accessible and only minimally invasive
surgery is necessary to harvest them; (ii) they are suitable
candidates for autologous transplantation, which would avoid
rejection of the transplant and graft-versus-host disease due to
immunomodulation (Paus et al. 2005); and (iii) there is no
evidence for tumor formation (Sieber-Blum et al. 2004).
Besides, the hair follicle is an immune-privileged site indicat-
ing HFBSC tolerance in xenogeneic and allogeneic transplan-
tations (Paus et al. 2005). In previous studies, we were able to
isolate HFBSCs and investigate their proliferation rate, dou-
bling time and cellular senescence as well as their capability to
adapt a neuronal phenotype (Gho et al. 2015; Schomann et al.
2017; Schomann et al. 2016).
However, successful translation of stem cell-based thera-
pies in the clinics will require robust preclinical testing and
validation, focusing on consensual definitions of terms and the
elucidation of the cells’ exact mechanism of action (Jendelova
et al. 2016). An integral part of this is the requirement to
monitor the extension of the TBI and response to treatment
in a non-invasive manner, which could be facilitated by the
application of multimodal imaging tools.
In order to regenerate neural tissue, transplanted stem cells
have to survive, differentiate into neurons and/or glial cells
and seek appropriate neuronal connections in order to achieve
functional neuronal repair. Visualization of the migration and
the fate of the transplanted stem cells in the injured brain in
living animals could provide direct monitoring of the cells’
behavior after transplantation.
The aim of this study is to combine multimodality imaging
technologies, such as optical imaging by means of biolumi-
nescence imaging (BLI) and magnetic resonance imaging
(MRI), to investigate in vivo the behavior of transplanted
HFBSCs cells in a mouse model of TBI (Mezzanotte et al.
2011; Mezzanotte et al. 2017). The ultimate goal is to achieve
a better understanding of the mechanism of recovery (e.g., cell
replacement, support of the microenvironment, or a combina-
tion of both). This may ultimately contribute to a better strat-
egy towards the promotion of neural tissue regeneration.
For this purpose, HFBSCs were transfected with a
lentiviral vector containing a construct that is composed of a
promoter and genes coding for both codon-optimized firefly
luciferase (Luc2) and copepod green fluorescent protein
(copGFP), in which the latter demonstrates a high fluores-
cence quantum yield and is more stable at a wide range of
temperatures. Both genes are coupled via a T2A-like se-
quence, which mediates co-translational cleavage and, hence,
results in bicistronic expression of copGFP and Luc2 (Abbas
et al. 2000). The promoter is either the constitutively active
elongation factor 1α (EF1α) or the promoter of doublecortin
(DCX), which is a neuronal migration protein and early neu-
ronal marker (Tennstaedt et al. 2015).
Additionally, transduced cells were loaded with
ferumoxytol, which is a superparamagnetic iron oxide
(SPIO) nanoparticle, in order to confirm their anatomical lo-
cation by means of MRI in vivo (Pirko et al. 2005).
Ferumoxytol is an FDA-approved drug for treatment of iron
deficiency anemia and has been successfully used to image
MSCs or macrophages loaded with heparin-protamine-
ferumoxytol (HPF) complexes in preclinical studies
(Khurana et al. 2012; Thu et al. 2012).
Material and methods
Cell culture
Hair follicles were dissected out from the whisker pads of
healthy adult (> 23 days) male and female surplus mice (strain
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C57Bl/6), as previously described (El Seady et al. 2008; Gho
et al. 2016). Isolation of HFBSCs from the bulge region of the
hair follicle was described elsewhere (Gho et al. 2016;
Schomann et al. 2016; Sieber-Blum et al. 2004).
Selected HFBSCs were cultured on poly-D-lysine-coated
(PDL; Sigma-Aldrich, St. Louis, MO, USA; 0.01 mg/ml in
distilled water) cell culture-treated 12-well plates (TPP
Techno Plastic Products AG, Trasadingen, Austria) in basic
growth medium (BGM) and maintained in a humidified incu-
bator at 37°C and 5% CO2. BGM, modified from Nguyen
et al. (Nguyen et al. 2013), consists of DMEM/Ham’s F-12
1:1 (Biochrom AG, Berlin, Germany), 1% GlutaMax™
(100×; Gibco, Bleiswijk, the Netherlands) and 1% antibiotic/
antimycotic solution (100×; Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS; Gibco), 2% B-27® sup-
plement without vitamin A (50×; Gibco), 1% N-2 MAX me-
dia supplement (100×; R&D Systems™, Minneapolis, MN,
USA), recombinant human basic fibroblast growth factor
(20 ng/ml; R&D Systems) and recombinant human epidermal
growth factor (20 ng/ml; R&D Systems). The cultures were
passaged, as previously described, after 60–70% confluence
was reached (Gho et al. 2016; Schomann et al. 2016).
HFBSCs were frozen in 10% DMSO in FBS and stored at
− 80°C until use. After thawing, HFBSCs were cultured in
BGM on PDL-coated dishes (TPP Techno Plastic Products
AG) and used for subsequent experiments.
Lentiviral vector production and transduction
of HFBSCs
HFBSCs were transduced with a third-generation lentiviral
vector containing the sequences for Luc2 and copGFP.
Details on these reporter molecules as well as their cloning
and recombination procedures have been reported previously
(Boehm-Sturm et al. 2014; Löw et al. 2010; Mezzanotte et al.
2013). In brief, lentivirus particles were generated bymeans of
transfection of HEK293 cells with packaging plasmids and the
plasmid pCDH-EF1-Luc2-T2A-copGFP or pCDH-DCX-
Luc2-T2A-copGFP (Schomann et al. 2016). Virus was quan-
tified by antigen-capture ELISA, measuring HIV p24 levels
(ZeptoMetrix Corporation, NY, USA). For transduction,
HFBSCs were resuspended in BGM. Pseudoviral particles
containing the copGFP-Luc2 constructs, using 40 ng virus
per 1 × 105, were added to the cells. Transduced HFBSCs
were stored at − 80°C until use.
Lentiviral vector production and stem cell transduction
were performed under the appropriate biosafety level condi-
tions (ML-II) in accordance with the National Biosafety
Guidelines and the Regulations for Research on Genetically
Modified Organisms. Procedures and protocols were
reviewed and approved by the LUMC Biosafety Committee
(GMO permit 00-026).
Fluorescence microscopy
Transduced HFBSCs containing the copGFP-Luc2 construct
were plated and allowed to attach in PDL-coated 12-well cell
culture plates. Expression of copGFP was observed using an
Olympus IX70 epi-illumination fluorescence microscope
(FITC filter settings) with a Leica DFC340 FX digital color
camera (Leica Camera AG, Wetzlar, Germany). Images were
acquired and digitally stored using Leica Application Suite
Advanced Fluorescence (LAS-AF) version 1.9 software.
In vitro differentiation
Expression of copGFP under regulation of the DCX promoter
was investigated by differentiating pCDH-DCX-Luc2-T2A-
copGFP-transduced HFBSCs, according to a previously
established neural differentiation protocol (Gho et al. 2016;
Schomann et al. 2016). pCDH-EF1α-Luc2-T2A-copGFP-
transducedHFBSCs served as controls. Briefly, 2.5 × 105 cells
were seeded via the side into PDL-coated wells containing
PDL-coated cover glasses (Thermo Scientific, Waltham,
MA, USA) in a to ta l vo lume of 500 μ l BGM.
Differentiation was induced by replacing 250 μl mediumwith
300 μl induction medium (IM). IM consists of DMEM/Ham’s
F-12 1:1 supplemented with 1.5 mM cAMP (Sigma-Aldrich),
1% GlutaMax (Life Technologies), 10 ng/ml NGF, 10 ng/ml
GDNF, 10 ng/ml BDNF (all fromR&DSystems) and 2%B27
with vitamin A (Life Technologies). Subsequently, cultures
were allowed to differentiate for at least 60 h without distur-
bance, followed by an additional substitution of 250 μl medi-
um with 300 μl IM.
Loading of HFBSCs with HPF complexes
HFBSCs containing the copGFP-Luc2 construct were loaded
with HPF complexes, according to the procedure of Thu et al.
(Thu et al. 2012). An amount of 4 × 106 cells were re-
suspended in serum-free BGM containing 2 IU/ml sodium
heparin (LEO Pharma, Amsterdam, the Netherlands),
60 μg/ml protamine hydrochloride (MEDA Pharma BV,
Amstelveen, the Netherlands) and 50 μg/ml ferumoxytol
(Rienso®, Takeda Pharma A/S, Roskilde, Denmark), which
was then followed by incubation at 37°C for 2 h. An equal
amount of BGM containing 20% FBSwas added, upon which
the cells were transferred to PDL-coated dishes and incubated
in a humidified incubator with 5% CO2 at 37°C. After 24 h,
the cells were firstly washed with phosphate-buffered saline
(PBS) and then with PBS containing heparin (10 IU/ml). The
cells were passaged by adding pre-warmed (37°C) balanced
salt solution containing 0.05% trypsin and 0.02% EDTA.4Na
(Gibco Life Technologies) to the culture dish, before being
incubated for 2 min. Cells were collected and re-suspended
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in PBS at a concentration of 5 × 104 cells/μl and stored at 4°C
until transplantation.
Detection of ferumoxytol
To visualize HPF complexes that were endocytosed by
HFBSCs, cells were fixed with pre-warmed 1% formaldehyde
in PBS directly after incubation. Fixed ferumoxytol-loaded
HFBSCs and mouse brain cryosections were pre-treated with
3% H2O2 in methanol for 30 min to inhibit endogenous per-
oxidase activity. This was followed by washing in distilled
water for 30 min. Iron oxide-containing ferumoxytol was vi-
sualized using Perls’ Prussian blue method, followed by 3,3′-
diaminobenzidine (DAB) intensification (Meguro et al. 2007).
Cells were then incubated in 1% potassium ferrocyanide
(K4Fe(CN)6.3H2O) with 1% HCl in distilled water for
30 min, which was then followed by several washes in dis-
tilled water (3 × 10 min). Next, the specimens were incubated
in the dark for 10 min in a solution containing 0.1% 3,3′-
diaminobenzidine, 4% HCl and 0.03% H2O2 in PBS. This
was followed by 3 washes in distilled water (5 min each) to
stop the reaction. Specimens were subsequently mounted in
Roti®-Mount FluorCare mounting medium (Carl Roth
GmbH + Co. KG, Karlsruhe, Germany) and examined with
a Leica DM5500B microscope with a Leica DFC 450C color
camera. Digital images were acquired and stored using Leica
Application Suite (LAS V4.5) software.
Animals and TBI
Animal care and handling were in accordance with the guide-
lines and regulations as stipulated by the Dutch Experiments
on Animals Act (WoD) and the European Directive on the
Protection of Animals Used for Scientific Purposes
(2010/63/EU). All applicable institutional and national guide-
lines for the care and use of animals were followed.
Healthy 8-week-old female CD1-nude mice (n = 10;
Charles River, Chatillon-sur-Chalaronne, France) were used
for the transplantation experiments. Mice were housed in the
Animal Care Facility of Leiden University Medical Center
(LUMC, the Netherlands) under standard housing conditions
(group cages with enriched environment, food and water ad
libitum; diurnal light cycle (12 h light, 12 h dark), temperature
21°C; humidity 60%). The use of the animals was approved
by the Animal Experiments Committee of the Leiden
University Medical Center (DEC permits 10065, 11198/3,
and 13024/1).
Anesthesia was induced for all experiments with 4%
isoflurane in air (Teva Pharmachemie BV, Haarlem, the
Netherlands) and mice were kept under anesthesia with
1.5% isoflurane in air. TBI was induced using a liquid nitro-
gen pre-cooled copper conical cylinder with a 3-mm diameter
tip. The cylinder was applied to the head of each mouse
approximately 3 mm left of the bregma for 40 s, so as to
induce traumatic brain damage as previously described
(Smith et al. 2012).
Two days after induction of the TBI, mice were anesthe-
tized with 2% isoflurane in air for transplantation of trans-
duced, ferumoxytol-loaded HFBSCs. A motorized,
computer-controlled stereotaxic instrument (Neurostar,
Tübingen, Germany) with mouse brain atlas integration and
real-time visualization of the injection site in the atlas space
was used for in vivo injections of HFBSCs into the mouse
brain. The anesthetized mouse was placed into the stereotaxic
instrument that fixes the skull with ear bars and a clamp sys-
tem that tightens against the jawbone and the palate. The co-
ordinates for injection were X (− 2), Y (2) and Z (1) relative to
the anterior bregma. The needle was navigated by a motorized
stereotactic frame utilizing StereoDrive software. Each injec-
tion was carried out within a standardized time frame, i.e.,
1 min injection time and 2 min deposition rest before needle
retraction, to prevent potential variations in the effect of shear-
ing forces. A total volume of 2 μl containing 2 × 105 HFBSCs
was stereotactically transplanted into the cerebral cortex of the
animals.
Bioluminescence imaging
Observation of survival (pCDH-EF1α-Luc2-T2A-copGFP)
and differentiation (pCDH-DCX-Luc2-T2A-copGFP) of
transplanted HFBSCs were achieved using BLI at 2, 14, 33
and 49 days after transplantation. Prior to imaging, mice re-
ceived an intraperitoneal injection of D-luciferin potassium
salt (Synchem UG & Co. KG, Felsberg, Germany).
Anesthesia was induced with 4% isoflurane in air and mice
were kept under anesthesia with 1.5% isoflurane in air. Images
were acquired 15 min after injection of D-luciferin
(150 mg/kg) using 30-s exposure, open filter, field of view C
(default setting), f/stop = 1 and medium binning for all biolu-
minescence measurements. All imaging measurements were
performed with the IVIS® Spectrummultimodal imaging sys-
tem (Caliper Life Sciences, Hopkinton, MA, USA), which
combines laser scan surface topography with BLI, with the
stage warmed to 37°C. Image acquisition and analysis were
performed with Living Image version 4.2.1 software (Caliper
Life Sciences).
Magnetic resonance imaging
In addition to BLI, ferumoxytol-loaded HFBSCs were imaged
after their transplantation into the mouse brain with TBI using
MRI to investigate the exact location of the stem cells at 1 and
48 days after transplantation. MRI was performed with a 7-T
Bruker PharmaScan® 70/16 (Bruker Biospin, Ettlingen,
Germany) equipped with a BGA-9S 300 mT/m gradient sys-
tem and a conventional 23-mm birdcage transmit-and-receive
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radio-frequency (RF) coil (Bruker Biospin). Mice were initial-
ly anesthetized with 4% isoflurane in air and kept under anes-
thesia with 1.5% isoflurane in air throughout the imaging pro-
cedure. Mice were placed in the RF coil, fixed in the bed with
ear bars and kept warm using a water-heated pad with thermo-
coupling to control mouse temperature. Respiration rate and
temperature were measured continuously. After an initial lo-
calization scan, T2*-weighted three-dimensional fast low-
angle shot (FLASH) sequences were used to visualize the
mouse. Optimal sequence parameters were as follows: repeti-
tion time (TR), 100 ms; effective echo time (TE), 13 ms; im-
aging matrix size, 128 × 128 × 64; final voxel resolution of
219 × 219 × 250 μm; and a FOV of 28 × 28 × 16 mm. Data
acquisition, image reconstruction and visualization were
achieved with Paravision® 6.0.1 software (Bruker Biospin,
Ettlingen, Germany). Images were processed using ImageJ
image analysis software (https://imagej.nih.gov/ij/plugins/
cell-counter.html; version 1.47; US National Institutes of
Health, Bethesda, MD, USA).
Immunohistochemistry
After 58 days, the anesthetized animals were fixed by means
of intracardial perfusion with 4% formaldehyde in PBS. After
decapitation, the brains were removed and stored in 1% form-
aldehyde in PBS at 4°C until further processing. Next, speci-
mens were embedded in Tissue-Tek® O.C.T.™ (Sakura
Finetek Europe B.V., Alphen aan den Rijn, the Netherlands)
compound and frozen for cryosectioning at − 20°C. Frozen
mouse brains were cut with the Microtome Cryostat HM
500 OM (MICROM International GmbH, Walldorf,
Germany), 10 μm brain sections were transferred onto KP
Plus slides (Klinipath B.V., Duiven, the Netherlands) and the
slides were stored at − 20°C.
For immunohistochemistry, sections were processed as
previously described (Gho et al. 2016). This procedure was
also followed for the cultured cells. Primary and secondary
antibodies used in this study are listed in Table 1. For all
stainings, proper positive and negative controls were used.
Adult human dermal fibroblasts (HDFa) from ScienCell
(catalog number: 2320; ScienCell, Carlsbad, CA, USA)
were obtained from the donors after signed informed con-
sent and in compliance with local, state and federal laws
and regulations. Nuclei were counterstained with 1:1000
DAPI (Invitrogen) in PBS for 15 min. The specimens were
mounted in a drop of Roti®-Mount FluorCare (Carl Rothi
GmbH+Co. KG, Karlsruhe, Germany). All specimens were
examined with a Leica DM5500 B fluorescence micro-
scope (filter settings: TXR, Cy7, FITC, and DAPI),
equipped with a Leica DFC365 FX digital camera.
Digital images were acquired and stored using Leica
Application Suite X (LAS X) software.
Statistical analysis
Statistical analyses of the data were performed using
GraphPad Prism 6.02 and SPSS Statistics version 20.0.0.1
software (IBM Corporation, Armonk, NY, USA). A multiple
t-test was applied to the cytokine assay data and data were
expressed as mean ± standard error of the mean (SEM). A
one-way ANOVAwith Bonferroni’s multiple comparison test
and 95% confidence interval was applied to the BLI data and
data were expressed as mean ± SEM.
Results
In vitro differentiation of transduced HFBSCs
HFBSCs, transduced with the pCDH-EF1α-Luc2-T2A-
copGFP gene construct, constitutively express both Luc2
and copGFP at equimolar ratios. Prior to differentiation, the
HFBSCs exhibited a bright green-fluorescent signal and nor-
mal morphologies (Fig. 1a–a″). The merged image demon-
strates that all cells were successfully transduced with the
reporter gene construct (Fig. 1a″). After induction of neuronal
differentiation, HFBSCs adopted neuronal morphologies
within 7 days as shown in the fluorescence and phase-
contrast images (Fig. 1b–b″).
Under the regulation of the promoter for the neuronal mi-
gration protein DCX, HFBSCs that were transduced with the
pCDH-DCX-Luc2-T2A-copGFP construct did not express
copGFP (or Luc2) during standard cell culture as marked by
the absence of any fluorescent signal (Fig. 1c–c″). However,
after induction of neuronal differentiation, HFBSCs showed
both neuronal morphologies and copGFP expression under
regulation of the DCX promoter within 7 days (Fig. 1d–d″).
Confirmation of ferumoxytol uptake by HFBSCs
To confirm that HFBSCs could take up theMRI contrast agent
ferumoxytol, we performed Perls’ Prussian blue staining with
DAB intensification on transduced cells loaded with HPF
complexes. While the cells constitutively expressed copGFP
(Fig. 1e), Perls’ Prussian Blue staining with DAB intensifica-
tion revealed the presence of iron oxide within 92.2 ± 1.1% of
the cells as marked by intracellular deposits of a brown pre-
cipitate (Fig. 1e–e″).
Bioluminescence imaging of HFBSCs transduced
with pCDH-EF1α- and pCDH-DCX-Luc2-T2A-copGFP
in mice with TBI
After transplantation, the bioluminescent signal of pCDH-
EF1α-Luc2-T2A-copGFP-transduced HFBSCs showed a
slow and stable increase over a period of 49 days (Fig. 2a–a
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‴). Cells transduced with the pCDH-DCX-Luc2-T2A-
copGFP gene construct revealed a faint or absent biolumines-
cence, 2 days after transplantation (Fig. 2b′–b‴). However,
representative overlays show that a distinct bioluminescent
signal emanated from the injection site within 14 days (Fig.
2b′) and peaked 33 days after transplantation (Fig. 2b″).
Interestingly, the bioluminescent signal dropped below initial
levels and almost vanished 49 days after transplantation of
transduced HFBSCs (Fig. 2b‴). A strong bioluminescent sig-
nal was obtained from transplanted HFBSCs containing the
pCDH-EF1α-Luc2-T2A-copGFP construct, while it was not
significantly different between the days of the measurements
(one-way ANOVA, p = 0.14) (Fig. 2c). The bioluminescent
signal from pCDH-DCX-Luc2-T2A-copGFP-transduced
HFBSCs initially increased over the period of 33 days and
thereafter steadily decreased, which was statistically signifi-
cant (one-way ANOVA, p = 0.048; Fig. 2c).
MRI of TBI mice transplanted
with ferumoxytol-loaded HFBSCs
In order to enable visualization of the cells by means of MRI,
HFBSCs were loaded with ferumoxytol prior to transplanta-
tion. The TBI lesion, which was induced 2 days before trans-
plantation of the HFBSCs, was clearly visible on the MRI due
to iron-rich, clotted erythrocytes (Fig. 3a, asterisks). In addi-
tion to the lesion, the transplanted ferumoxytol-loaded
HFBSCs (Fig. 3a, dotted boxes) were also visible. Over the
course of 8 days, the hypointense signal from the iron-
containing erythrocytes at the site of the TBI lesion
completely disappeared (data not shown; cf., Fig. 3a′, day
48). Ferumoxytol-loaded HFBSCs were visible as a
hypointense area within the mouse brain 1 day after injection
(Fig. 3b, day 1, dotted boxes). Subsequent MRI of mice re-
vealed that a hypointense area from ferumoxytol persisted
within the brain for at least 48 days and showed migration
of the hypointense signal towards the site of TBI (Fig. 3b′,
day 48, arrow).
Histochemical staining
The stability of copGFP protein enabled visualization of the
fluorescent protein in cryosections of mouse brains without
additional immunohistological staining for copGFP
Table 1 Antibodies
Type Antibody Host Clon Company Cat. No. Localization Dilution Control
Primary CopGFP Rabbit polyclonal Evrogen AB513 Cytoplasm 1:200 Luc2-copGFP
transduced cells
Primary Doublecortin (DCX) Rabbit polyclonal Abcam Ab18723 Cytoplasm 1:200 C17.2, Brain (Mouse)
tissue lysate -
normal tissue,
0 days old
Primary Fibronectin Rabbit polyclonal Sigma-Aldrich F3648 Extracellular matrix
glycoprotein
1:400
Primary GFAP Rabbit polyclonal DAKO Z0334 Cytoplasm 1:500 RT4-D6PT2
Primary Ki-67 Rabbit polyclonal Abcam ab15580 Nuclear 1:100 Human dermal
fibroblasts
Primary Laminin Rabbit polyclonal Dako Z009701 Extracellular matrix 1:200 RT4-D6P2T, MelbA,
HFBSCs
Primary Luc2 Mouse monoclonal DSHB DSHB-LUC-2 Cytoplasm 25:100 Luc2-copGFP
transduced cells
Primary Nestin 4D11 Mouse monoclonal Biosensis M-1385-100 Cytoplasm 1:300 C17.2 (NSCs), M14,
RT4-D6P2T
Primary NF-Pan Mouse monoclonal EMD Millipore NE1017 Cytoskeleton 1:1000 Mouse brain slices
Secondary Alexa Fluor™ 555 Goat polyclonal BioLegend 405,324 1:200
Secondary Alexa Fluor™ 750 Goat polyclonal Abcam ab175733 1:200
Fig. 1 In vitro differentiation and loadingwith ferumoxytol of transduced
HFBSCs. Prior to differentiation (day − 1) pCDH-EF1α-Luc2-T2A-
copGFP-transduced cells exhibited a bright green-fluorescent signal of
copGFP (a) and had normal morphologies (a″; phase contrast). The
merged image (a‴) demonstrates that all cells were transduced with the
reporter gene construct. Within 7 days, HFBSCs adapted neuronal
morphologies (b; copGFP fluorescence and b′; Phase contrast). Scale
bar is 100 μm. HFBSCs transduced with the pCDH-DCX-Luc2-T2A-
copGFP construct did not express copGFP (or Luc2) prior to
differentiation (day − 1) as indicated by the absence of a fluorescent
signal (c). However, cells expressed copGFP under regulation of the
DCX promoter as indicated by the green fluorescent signal 7 days after
start of the differentiation (d). HFBSCs also adapted neuronal
morphologies (d′; phase contrast). Scale bar is 100 μm. Perls’ Prussian
blue (PB) staining + DAB intensification stained ferumoxytol within the
cells as marked by a brown precipitate (e′). Faint copGFP fluorescence
persisted through the staining process as can be observed in the
fluorescence (e) and merged images (e″). Scale bar is 100 μm
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(Fig. 4a–d and Fig. 5a–c, copGFP protein). However, we per-
formed an additional immunostaining of the cryosections for
copGFP (Figs. 4a′ and c′,) or Luc2 (Figs. 4b′, d′, and 5a′–c′) to
confirm the presence of pCDH-EF1α-Luc2-T2A-copGFP-
transduced HFBSCs. Furthermore, all cells that exhibited
green fluorescence from copGFP also showed staining for
the neural progenitor cell marker nestin (Fig. 4a″). A marker
for astrocytes in the central nervous system, GFAP, showed
staining in the mouse brain but not in HFBSCs (Fig. 4b″). The
depicted GFAP signal originates from glial cells surrounding
the copGFP expressing HFBSCs. Staining for the neural
marker neurofilament with NF-Pan was faint and restricted
to individual HFBSCs but colocalized with copGFP (Fig. 4c
″). Staining of the transduced HFBSCs for DCX was negative
(Fig. 4d″). In addition, the surrounding area of some green
fluorescent HFBSCs also stained for fibronectin (Fig. 5a″)
and laminin (Fig. 5b″). This indicates secretion of these extra-
cellular matrix proteins by the injected cells. Staining for the
proliferation marker Ki-67 was negative in transplanted
HFBSCs (Fig. 5c″) but positive in HFBSCs in vitro
(Table 2). Positive and negative controls showed the reliability
of the staining performed (data not shown). Table 2 compares
the immunostaining of cultured HFBSCs and the cryosections
of TBI mouse brains. Perls’ Prussian blue staining with DAB
i n t e n s i f i c a t i o n o f c r y o s e c t i o n s , wh i c h we r e
immunohistochemically stained for nestin (Fig. 6a) and lam-
inin (Fig. 6b), showed that HFBSCs (which also expressed
copGFP and stained for copGFP or Luc2) stained for
Fig. 2 Observation of Luc2 activity in TBI mice in vivo. Representative
overlays of pCDH-EF1α-Luc2-T2A-copGFP-transduced HFBSCs from
2 (a), 14 (a′), 33 (a″) and 49 days after transplantation (a‴). The
bioluminescent signal increased with relative stability over the course of
time. Representative overlays of HFBSCs transduced with pCDH-DCX-
Luc2-T2A-copGFP over the same period of time. No bioluminescent
signal was observed 2 days after transplantation (b). The signal
increased between 14 days (b′) and 33 days (b″) but was almost
undetectable after 49 days (b‴). Analysis of the bioluminescent signal
was measured 2, 14, 33 and 49 days after transplantation (c). The
bioluminescence data were normalized with the initial signal and
measured 2 days after transplantation, which depicts the trend of the
bioluminescent signal from HFBSCs over time. The bioluminescent
signal of pCDH-EF1α-Luc2-T2A-copGFP-transduced HFBSCs
increased steadily over the course of time, while the bioluminescence of
pCDH-DCX-Luc2-T2A-copGFP-transduced HFBSCs decreased after
33 days and was almost undetectable at 49 days
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ferumoxytol after 58 days in vivo (Fig. 6a′ and b′). However,
iron staining was also positive in the tissue surrounding the
graft, which may indicate uptake of iron by other cells, e.g.,
macrophages, (Fig. 6a″ and b″, merge). Reconstruction of
brain sections guided by fluorescence of copGFP (Fig. 6c)
reconfirmed that, after transplantation, HFBSCs were present
in the superficial cortex (where TBI was imaged by means of
MRI) as well as in the deep cortex (Fig. 6c′) and corpus
callosum (Fig. 6c″) next to the injection site as depicted in
Fig. 6d.
Discussion
We were able to show for the first time that HFBSCs can
survive and differentiate towards a neuronal cell lineage after
transplantation of these cells into the mouse brain by applying
in vivo multimodal imaging, i.e., BLI and MRI.
We established that HFBSCs tolerate genetic manipulation
and loading with nanoparticles in vitro in a previous study
(Schomann et al. 2016). For the present study, we
also loaded the HFBSCs with the (ultrasmall) SPIO nanopar-
ticle ferumoxytol, which has proven effective for in vivo
tracking of stem cells with high sensitivity by means of MRI
(Gutova et al. 2013; Khurana et al. 2013; Pirko et al. 2005;
Schieda 2013). We showed that HFBSCs take up HPF com-
plexes using the Perls’ Prussian blue method and DAB inten-
sification, which stains Fe3+ deposits within the cells.
In mice with TBI, the bioluminescent signal of HFBSCs
transduced with pCDH-EF1α-Luc2-T2A-copGFP remained
high over time, while bioluminescence of pCDH-DCX-
Luc2-T2A-copGFP-transduced HFBSCs was initially low. It
increased over a period of at least 33 days and completely
vanished afterwards, which indicated that BLI can be used
in tracking early differentiation in vivo. Tennstaedt et al. re-
ported the same bioluminescence pattern of human neural
stem cells transduced with Luc2 under regulation of the
DCX promoter in their in vivo study (Tennstaedt et al.
2015). Our discovery that the bioluminescent signal vanished
within 49 days after injection was also in line with the work of
Fig. 3 MRI of ferumoxytol-
loaded HFBSCs in TBI mice at
different Bregma levels in vivo.
Different sources of T2*-
weighted contrast are illustrated
in areas close to the TBI or more
remotely. The upper panel shows
representative scans of the region
containing the TBI lesion 1 day
(a) and 48 days after
transplantation (a′). The scan at
day 1 revealed a hypointense area
containing clotted iron-containing
erythrocytes (asterisk), which
vanished over the course of time.
Dotted box: injected cells. The
lower panel shows representative
scans of the transplanted
ferumoxytol-loaded transduced
HFBSCs over the same course of
time (b, b′). The dotted box at day
1 after transplantation shows the
location of ferumoxytol-
containing cells. Asterisk: clotted
erythrocytes. The hypointense
signal of ferumoxytol could also
be imaged at the transplantation
site at least 48 days after
transplantation. Scale bar is
200 μm
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Ladewig et al., who demonstrated decreased DCX expression
during cell maturation, which is likely due to the fact that
DCX is a marker expressed early on in neural differentiation
(Ladewig et al. 2008). In addition, we could rule out that the
decrease in bioluminescent signal was due to cell death since
the signal from pCDH-EF1α-Luc2-T2A-copGFP-transduced
HFBSCs, which constitutively express Luc2, remained con-
stant over the same period.
We checked for hypointense regions in the mouse brain by
means of MRI at 1 day after transplantation of ferumoxytol-
loaded transduced HFBSCs and again 48 days after transplan-
tation. Bryant et al. recently demonstrated that formation of
FHP complexes (ferumoxytol is the base component and hep-
arin and protamine are added to form the complexes) im-
proved the MRI contrast compared to HPF complexes
(ferumoxytol is added as a last component) (Bryant Jr. et al.
2017). However, in our case, HFBSCs showed a high uptake
of HPF complexes and could be clearly detected after trans-
plantation next to the TBI lesion (cortical region) in nudemice
at both time points. One day after transplantation, the MRI
showed hypointense spots in the cortex area, indicating the
presence of ferumoxytol. MRI and BLI data were combined
to show that cells were transplanted at the correct site and that
they remained viable and present in a detectable amount. The
MRI enabled visualization of ferumoxytol at the transplanta-
tion site after 48 days and we were able to observe changes in
the hypointense regions indicating migration of cells, most
likely HFBSCs as indicated by Perls’ Prussian blue staining
with DAB intensification for iron oxide in cryosections, to-
wards the area of TBI (Fig. 3b′, day 48, arrow). This is in line
with the finding of Zheng et al. who were able to image neural
stem cells for up to 87 days in vivo (Zheng et al. 2015).
It is of importance to mention that it is not possible to
correlate both modalities, BLI and MRI. Therefore, we used
Fig. 4 Immunohistochemical staining of HFBSCs constitutively
expressing Luc2 and copGFP. Sections of mouse brains containing
transduced HFBSCs exhibited native green fluorescence emitted by
copGFP after fixation, sectioning and staining of the sections (a, b, c, d;
green). Sections containing copGFP-expressing HFBSCs were stained
for either copGFP (a′ and c′) or Luc2 (b′ and d′). CopGFP-expressing
HFBSCs stained for copGFP (a′; red) and the neural progenitor cell
marker nestin (a″; gray). The merged image (a′′′′) shows colocalization
of copGFP (a′), nestin (a″) andDNA (a‴) of copGFP-expressing HFBSCs
in the mouse brain. HFBSCs, which expressed copGFP (b; green), also
stained for Luc2 (b′; red). GFAP (b″; gray) stained in the mouse brain but
is absent in HFBSCs (b‴; green/red). Transplanted HFBSCs (c/c′; green/
red) stained for NF-Pan (c″; gray). None of the copGFP-expressing
HFBSCs (d/d′; green/red) stained for DCX (d″). Scale bar = 50 μm
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BLI for quantitative data and MRI was applied to gain ana-
tomical information of the site of injection. In this way, we
took advantage of the anatomical resolution achievable with
MRI as well as the sensitivity of the BLI signal, together with
information about gene expression. With respect to the MRI
data, we only acquired T2*-weighted scans with a single echo.
In a recent study, Mishra et al. used multi-echo MRI scans to
measure the iron oxide load of MSCs (Mishra et al. 2018).
However, it was not possible to reproduce this analysis due to
the scan settings used in our study. Moreover, the resolution of
the MRI is much lower than the size of the cells. This means
that also migration and dispersion of the cells from the local
injection volume to a much wider volume will result in a
different sub-voxel distribution of iron, again resulting in
changes in T2* relaxation that do not reflect true iron quanti-
fication. Therefore, we do not consider the quantification of
the T2* relaxation as a precise measure of the iron oxide load
of cells.
Fig. 5 Immunohistochemical staining for extracellular matrix and
proliferating cells. CopGFP-expressing HFBSCs in mouse brain
sections exhibited native fluorescence (a, b, and c; copGFP protein;
green). Additionally, sections were stained for Luc2 (a′, b′, and c′; red).
The surrounding area of some HFBSCs stained for fibronectin (a″; gray).
The vicinity of transplanted HFBSCs stained for laminin (b″; gray).
Staining for Ki-67 (c″; gray) was negative in sections containing
HFBSCs (green/red). Scale bar = 50 μm
Table 2 Overview of staining pattern
Antibody Cultured HFBSCs Transplanted
HFBSCs
Specification
HFBSCs copGFP Positive Positive Transduced HFBSCs expressing copGFP
Luc2 Positive Positive Transduced HFBSCs expressing Luc2
Neural Crest Nestin Positive Positive Neural crest cells and neuronal progenitors
Neuron DCX Negative Weakly positive Early neuronal development
NF-Pan Weakly positive Positive Neurons
Glial Cell GFAP Negative Negative Glial cells in the peripheral and central nervous system
ECM Fibronectin Negative Positive Cell adhesion, growth, migration, differentiation, neuron protection
Laminin Positive Positive Cell attachment, stimulates neuronal differentiation, promotion of
tissue survival
Other Ki-67 Positive Negative Proliferating cells
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Transduced HFBSCs maintained fluorescence after fixa-
tion, sectioning and (immune)staining. Therefore, we were
able to visualize the copGFP expressed by HFBSCs in cryo-
sections of mouse brains. We verified that this green fluores-
cence was obtained from copGFP and excluded auto-
fluorescence by staining the sections with primary antibodies
against either copGFP or Luc2, which were both expressed by
the transplanted cells. The transplanted HFBSCs showed
staining for the neural marker neurofilament (NF-Pan), which
is in line with previous findings (Ladewig et al. 2008;
Tennstaedt et al. 2015) but not for glial fibrillary acidic protein
(GFAP), which indicates their differentiation towards a neu-
ronal lineage. In addition, the majority of copGFP-expressing
HFBSCs in brain sections of TBI mice were positive for
nestin, a marker for NCSCs and neural progenitors,
underlining the neural differentiation potential of these stem
Fig. 6 Perls’ Prussian blue staining with DAB intensification of mouse
brain sections. Immunohistochemically stained sections from Fig. 4(a–a′′′′)
and Fig. 5(b–b′′′′) (IHC) were also stained with Perls’ Prussian blue with
DAB intensification. This showed that HFBSCs stain for ferumoxytol 58
days after transplantation in TBI mice (a′ and b′; ferumoxytol). The merged
image of the ferumoxytol staining and the corresponding
immunofluorescence image reveals colocalization of Fe3+ deposits and a
fluorescent signal (a″ and b″; merged). Scale bar is 25 μm. The native
fluorescence of the copGFP, which persists also after the preparation of
the brain sections, indicates the location of the HFBSCs within the mouse
brain (c; scale bar is 250μm), i.e., the cortex (c′; scale bar is 50μm) and the
corpus callosum (c″; scale bar is 100 μm; enlarged images of boxes).
Illustration of the injection site of HFBSCs in the mouse brain (d;
adapted from the Neurostar Robotic Stereotactic Software)
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cells. However, we can only speculate about their phenotype
when fully matured. We assume that HFBSCs, similar to the
skin-derived precursor cells, which are also derived from the
neural crest, would differentiate into peripheral neurons
(Fernandes et al. 2006; Fernandes et al. 2004). Staining for
DCX, a marker that is expressed early on in neural differenti-
ation, was negative, which confirmed our bioluminescence
results that, at this time point the cells passed their commit-
ment of neuronal differentiation and progressed towards a
more mature neuronal state. Underlining this finding was the
fact that the transplanted cells were not positive for cell pro-
liferation marker Ki-67, indicating that HFBSCs did not enter
a harmful, tumorigenic state of uncontrolled proliferation.
Surprisingly, transplanted cells showed positive staining for
the extracellular matrix proteins laminin (all) and fibronectin
(some). Laminin and fibronectin have been shown to play
important roles in neurite guidance regeneration of tissue after
TBI and motility of neural crest cells, which further support
the potential role of HFBSCs in tissue regeneration in TBI
(Evans et al. 2007; Strachan and Condic 2008; Tate et al.
2007).
After identifying transplanted HFBSCs within brain sec-
tions of TBI mice, we stained these sections for Fe3+, a com-
ponent of ferumoxytol. The staining revealed that HFBSCs
still contained ferumoxytol after 58 days in vivo. Our results
indicate that ferumoxytol was partially excreted by HFBSCs
and taken up by cells in the surrounding tissue, e.g., macro-
phages. However, a substantial part of the hypointense signal
on theMRI originates from ferumoxytol-containing HFBSCs.
Moreover, our finding of fluorescent cells, which are local-
ized in the corpus callosum and the site of TBI (in the super-
ficial cortex) in brain sections, may indicate that HFBSCs
participate in recovery after neural trauma. The mechanism
of how this recovery might occur remains unknown.
However, the need to further elucidate potential recovery per-
sists. Recovery may occur by cell replacement due to differ-
entiation, through paracrine effects, or combination of both. In
case both mechanisms occur, a strategy could be to transplant
cells in biologic scaffolds made of brain-derived extracellular
matrices in the form of hydrogels with the aim to enhance
survival and promote angiogenesis (Crapo et al. 2014). On
the other hand, if the paracrine effect prevails, a therapeutic
strategy based on the sole administration of exosomes derived
from HFBSCs, i t would represent an alternat ive
neurorestorative therapy. Moreover, the exosomes could be
tailored to maximize clinical benefits (Zhang et al. 2019).
Conclusion
In conclusion, this first study about HFBSCs transplantation
in a mouse model of TBI indicates that HFBSCs are able to
survive in mice brain and the procedure is safe in mice. In this
relative short time, most of the transplanted cells remained
nestin positive but some individual cells undergo differentia-
tion towards a neuronal cell lineage and a part could be found
in the lesioned area. Because of all this evidence, HFBSCs
qualify as possible candidates for cell-based therapy of TBI,
although further studies are required to elucidate their ability
to enhance repair processes and improve cognitive function.
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